Potency and penetration of telavancin in staphylococcal biofilms

International Journal of Antimicrobial Agents

Volumn 46, Issue 4, 2014, Pages 451-455

  Kirker, Kelly R ^a   Fisher, Steve T ^a   James, Garth A ^a  

^a MONTANA STATE UNIVERSITY   (United States)

Author keywords

Biofilm; Staphylococcal; Telavancin

Indexed keywords

TELAVANCIN; AMINOGLYCOSIDE; ANTIINFECTIVE AGENT;

ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL GROWTH; BACTERIAL STRAIN; BIOFILM; CONFOCAL LASER MICROSCOPY; CONTROLLED STUDY; DRIP FLOW REACTOR; DRUG PENETRATION; DRUG POTENCY; FLUORESCENCE ANALYSIS; HETEROGENEOUSLY VANCOMYCIN INTERMEDIATE STAPHYLOCOCCUS AUREUS; IMAGE ANALYSIS; INCUBATION TIME; METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS; METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS EPIDERMIDIS; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REACTOR; STAPHYLOCOCCUS; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS; VANCOMYCIN INTERMEDIATE STAPHYLOCOCCUS AUREUS; DRUG EFFECTS; HUMAN; PHYSIOLOGY;

AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; BIOFILMS; HUMANS; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS;

EID: 84948570996     PISSN: 09248579     EISSN: 18727913     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2015.05.022     Document Type: Article

References (15)

1. Scott II RD. The direct medical costs of healthcare-associated infections in U.S.hospitals and the benefits of prevention. Atlanta, GA: US Centers for DiseaseControl and Prevention; 2009. p. 1-13.
2. Costerton JW, Stewart PS, Greenberg EP. Bacterial biofilms: a common cause ofpersistent infections. Science 1999;284:1318-22.
3. Leadbetter MR, Adams SM, Bazzini B, Fatheree PR, Karr DE, Krause KM, et al.Hydrophobic vancomycin derivatives with improved ADME properties: dis-covery of telavancin (TD-6424). J Antibiot (Tokyo) 2004;57:326-36.
4. Higgins DL, Chang R, Debabov DV, Leung J, Wu T, Krause KM, et al. Telavancin,a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cellmembrane integrity in methicillin-resistant Staphylococcus aureus. AntimicrobAgents Chemother 2005;49:1127-34.
5. Gander S, Kinnaird A, Finch R. Telavancin: in vitro activity against staphylococciin a biofilm model. J Antimicrob Chemother 2005;56:337-43.
6. LaPlante KL, Mermel LA. In vitro activities of telavancin and vancomycin againstbiofilm-producing Staphylococcus aureus, S. epidermidis, and Enterococcus fae-calis strains. Antimicrob Agents Chemother 2009;53:3166-9.
7. Smith K, Gemmell CG, Lang S. Telavancin shows superior activity to vancomycinwith multidrug-resistant Staphylococcus aureus in a range of in vitro biofilmmodels. Eur J Clin Microbiol Infect Dis 2013;32:1327-32.
8. Dice B, Stoodley P, Buchinsky F, Metha N, Ehrlich GD, Hu FZ. Biofilm formationby ica-positive and ica-negative strains of Staphylococcus epidermidis in vitro.Biofouling 2009;25:367-75.
9. Goeres DM, Hamilton MA, Beck NA, Buckingham-Meyer K, Hilyard JD, Loet-terle LR, et al. A method for growing a biofilm under low shear at theair-liquid interface using the drip flow biofilm reactor. Nat Protoc 2009;4:783-8.
10. Buckingham-Meyer K, Goeres DM, Hamilton MA. Comparative evalua-tion of biofilm disinfectant efficacy tests. J Microbiol Methods 2007;70:236-44.
11. Hlady V, Buijs J, Jennissen HP. Methods for studying protein adsorption. Meth-ods Enzymol 1999;309:402-29.
12. Stewart PS, Davison WM, Steenbergen JN. Daptomycin rapidly pene-trates a Staphylococcus epidermidis biofilm. Antimicrob Agents Chemother2009;53:3505-7.
13. Rani SA, Pitts B, Stewart PS. Rapid diffusion of fluorescent tracers into Staphy-lococcus epidermidis biofilms visualized by time lapse microscopy. AntimicrobAgents Chemother 2005;49:728-32.
14. Theravance I. Package insert; 2013. http://www.vibativ.com/[accessed01.06.15].
15. Saraf LJ, Wilson SE. Telavancin, a new lipoglycopeptide antimicrobial, incomplicated skin and soft tissue infections. Infect Drug Resist 2011;4:87-95.